TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26292178
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive stimulation therapy (iCST)
Study: 2095341
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (ES) 1000 mg
Study: 2095341
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 800 mg
Study: 27683800
Drug: Increased dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosing to vedolizumab every 4 weeks (from every 8 weeks)
Study: 19838998
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (133 mg or 200 IUs)
Study: 14987324
Drug: Peginterferon plus
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon plus ribavirin combination therapy
Study: 14987324
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum interferon-gamma-inducible protein-10 levels greater than 299 pg/mL
Study: 14987324
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum interferon-gamma-inducible protein-10 levels lower than 299 pg/mL
Study: 11476461
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg twice daily) in group 1p (N = 14)
Study: 11476461
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg twice daily) in group 2p (N = 14)
Study: 11476461
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg twice daily) in group 3p (N = 11)
Study: 11476461
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy in groups 1c, 2c, and 3c (N = 24)
Study: 9489812
Drug: Community based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community based physical therapy (PT) program, at least 4 visits or 3 hours of PT over 6 weeks
Study: 3166359
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg administered orally or intravenously
Study: 26096139
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg + 5 mg prednisone twice daily) + low-fat meal
Study: 11481622
Drug: Triple antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antigen vaccine
Study: 9570610
Drug: Meperidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 40 mg (Group A)
Study: 9570610
Drug: Meperidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 40 mg followed by naloxone 0.04 mg (Group B)
Study: 9570610
Drug: Meperidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 40 mg followed by naloxone 0.2 mg (Group C)
Study: 18608041
Drug: Atorvastatin 40-80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40-80 mg/d
Study: 18608041
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg followed by 75 mg/d
Study: 14711140
Drug: Intramuscular alefacept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular alefacept 15 mg
Study: 11044791
Drug: No medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medical treatment (nontreated group)
Study: 8259610
Drug: PRP-D vaccine
Normalized name: Hib (PRP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D vaccine coadministered with Di-Te-Pol
Study: 3862463
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate plus intermediate dose methotrexate
Study: 30478001
Drug: Azithromycin oral
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin oral solution 10 mg/kg per day for 3 days
Study: 18672400
Drug: PBT2 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBT2 250 mg
Study: 15467775
Drug: Orlistat, 120
Normalized name: Orlistat, 120 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat, 120 mg three times daily with hypocaloric diet
Study: 14650571
Drug: Experimental acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental acupuncture treatment (specific acupuncture body points related to menopausal symptoms)
Study: 8072048
Drug: Experimental acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental acupuncture treatment
Study: 14650571
Drug: Experimental acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental acupuncture treatment and Comparison acupuncture treatment
Study: 4061000
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with aspiration of 3 ml of CSF
Study: 4061000
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with a mixture of 3 ml of aspirated CSF and 3 ml of 0.5% isobaric bupivacaine
Study: 21873358
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg capsules
Study: 21873358
Drug: Warfarin 5
Normalized name: warfarin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 5 mg tablets
Study: 16286519
Drug: Calorie-restricted low-dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-restricted low-dairy diet (CR) - approximately 1 serving dairy/day, 500 mg calcium/day
Study: 9517760
Drug: 27.5 mg
Normalized name: lipase 27.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27.5 mg folic acid supplementation per week
Study: 2955205
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (2 mg/day)
Study: 22117984
Drug: Combined inhalation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inhalation and intravenous anaesthesia (sevoflurane 1.0 vol% in 50% air plus propofol‐remifentanil [target blood concentrations 1.5 ‐ 2.5 μg/ml and 2.5 ‐ 3.5 ng/ml])
Study: 22117984
Drug: Sevoflurane (thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (thiopental sodium 4 ‐ 5 mg/kg and sevoflurane 2.0 ‐ 2.5 vol% in 50% air)
Study: 9892883
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg)
Study: 10940797
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 400 mug twice daily
Study: 8365089
Drug: Soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble human insulin (0.15 U kg‐1 body weight)
Study: 6149992
Drug: Cimetidine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1,000 mg per day)
Study: 2196208
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg per day)
Study: 6149992
Drug: Cimetidine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (120 mg per kg body weight)
Study: 6149992
Drug: Ranitidine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (120 mg per kg body weight)
Study: 23959571
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment (IT)
Study: 22108529
Drug: Coach-administered modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coach-administered modified warm-up consisting of various swimming modes, intensities, and rest intervals for 20 minutes
Study: 20698844
Drug: 0.1% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% DHEA cream
Study: 8641599
Drug: Subcutaneous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fluids (s.c.)
Study: 6095468
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin 100 mg/kg on 2 successive days
Study: 29408986
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 every 3 weeks)
Study: 25944156
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g topical TXA
Study: 25944156
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous TXA
Study: 22110105
Drug: Sodium excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium excretion > 7 g/day
Study: 22110105
Drug: Potassium excretion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium excretion 2-2.49 g/day
Study: 20969563
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no topical agent)
Study: 8612379
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg orally three times a day for 2 days
Study: 26584404
Drug: 4g day(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g day(‐1) paracetamol
Study: 16362843
Drug: Sertraline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline with late partial sleep deprivation
Study: 9564184
Drug: Almitrine 75
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 75 mg
Study: 7701045
Drug: Ipsapirone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 20 mg
Study: 29497863
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid lowering treatment (specific intervention not detailed)
Study: 26378067
Drug: 0.08 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg/kg oxycodone (Group O)
Study: 26378067
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg fentanyl (Group F)
Study: 23296279
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drugs (non-nitrate group)
Study: 14633813
Drug: Control (NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (NPH or MIX insulin)
Study: 11077130
Drug: Sustained-release moxonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release moxonidine 0.9 mg bid
Study: 8354296
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate suspension given b.i.d. for seven days
Study: 8354296
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (b.i.d. and t.i.d.)
Study: 26492167
Drug: Ablation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation treatment (coagulation) in Group A (small endometriomas)
Study: 26492167
Drug: Excision treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excision treatment in Group A (small endometriomas)
Study: 26492167
Drug: Excision treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excision treatment in Group B (large endometriomas)
Study: 12488664
Drug: Standard course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard course ciprofloxacin (15 mg/kg every 12 h for 5 days)
Study: 9400449
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 10 micrograms alprostadil plus genital plus audiovisual sexual stimulation
Study: 9400449
Drug: Re-dosing of
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-dosing of 10 micrograms alprostadil
Study: 7654128
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride 50 mg/d
Study: 7654128
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride 100 mg (single dose)
Study: 7654128
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride 150 mg/d
Study: 2667598
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of CGP 38 560 A at doses of 50, 125, and 250 micrograms kg‐1
Study: 7001331
Drug: Vidarabine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine therapy
Study: 28389705
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (3.0/1.5 mU kg‐1 min‐1) under hyperglycaemic ketotic conditions (KET)
Study: 28389705
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (3.0/1.5 mU kg‐1 min‐1) under euglycaemic conditions (CTR)
Study: 23122669
Drug: DEX 0.5
Normalized name: Stri-Dex 0.5 % Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0.5 μg/kg (group D)
Study: 21183500
Drug: Cardiac troponin
Normalized name: Cardiac troponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac troponin I (cTnI) ≥0.03 ng/mL
Study: 21183500
Drug: Myeloperoxidase (MPO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloperoxidase (MPO) ≥670 pmol/L
Study: 10357331
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 20 mg every 12 h
Study: 10357331
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone 10 mg every 4 h
Study: 10357331
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone 10 mg every 4 h as needed
Study: 7892519
Drug: Daily alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alcohol intake and nutrient intake
Study: 7892519
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (more than 100 g ethanol per day)
Study: 1974100
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg carvedilol i.v.
Study: 333997
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.5 mg terbutaline
Study: 333997
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive doses of 0.25 mg terbutaline
Study: 333997
Drug: Four consecutive
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four consecutive doses of 0.125 mg terbutaline
Study: 29211735
Drug: Directed patrol
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed patrol by uniformed, unarmed security agents
Study: 24499166
Drug: Egitromb 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egitromb 300 mg at admission followed by 8 days of 75 mg Egitromb daily (Group A, n = 28)
Study: 24499166
Drug: Plavix 300
Normalized name: Plavix 300mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix 300 mg at admission followed by 8 days of 75 mg Plavix daily (Group B, n = 25)
Study: 22184293
Drug: Intraperitoneal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal normal saline infusion (INSI)
Study: 9842842
Drug: Placebo (patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (patches and pills)
Study: 2514676
Drug: Cicletanine 150
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 150 mg/day
Study: 412646
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate moulded tablet ('Nitrostat')
Study: 412646
Drug: Generic compressed
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic compressed tablet
Study: 30646205
Drug: IIDEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIDEA treatment (10 sessions)
Study: 10036952
Drug: One-week treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week treatment with LPZ 30 mg once daily, AMPC 1500 mg twice daily, CAM 800 mg twice daily
Study: 12759560
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg triazolam (TRZ)
Study: 6989067
Drug: HRE (isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRE (isoniazid, rifampicin, ethambutol) for 2 months followed by H2R2 (isoniazid and rifampicin twice weekly) for 4 months
Study: 6989067
Drug: HRSZ (isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRSZ (isoniazid, rifampicin, streptomycin, pyrazinamide) for 2 months followed by 4HRE (isoniazid, rifampicin, ethambutol daily) for 4 months
Study: 6989067
Drug: Pyrazinamide included
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide included in the initial phase of treatment
Study: 6989067
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimens (6 months)
Study: 16361729
Drug: Topical oxytetracycline
Normalized name: oxytetracycline Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxytetracycline hydrochloride (tetracycline)
Study: 9605061
Drug: Intravenous ergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ergotamine (0.25 mg)
Study: 1620417
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg at 22 hours the night before surgery
Study: 1620417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 patients, no drugs)
Study: 6431812
Drug: Hydralazine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine therapy (100 mg orally every eight hours)
Study: 29523533
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1,000 mg/100 mL during surgery)
Study: 26739997
Drug: UMEC 500
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 500 µg
Study: 26739997
Drug: UMEC/VI 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 125/25 µg
Study: 26739997
Drug: UMEC/VI 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 500/100 µg
Study: 20406224
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (positive control)
Study: 16770616
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg ornidazole
Study: 28222627
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg three times daily
Study: 9393572
Drug: Endoscopic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic laser therapy (ELT) only using a ND‐Yag Laser system (Group I and II)
Study: 9393572
Drug: Endoscopic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic laser therapy (ELT) only (Group I and II)
Study: 24986531
Drug: 75-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g oral glucose tolerance test (OGTT) and three isocaloric (500 kcal) and isovolaemic (350 ml) liquid meals with varying fat content (2.5g, 10g, 40g)
Study: 484501
Drug: Oral quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine
Study: 9288408
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg)
Study: 19667286
Drug: BAL8557 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (100 mg isavuconazole) oral administration
Study: 16449476
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (up to 1 year)
Study: 16449476
Drug: Overall antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antidepressant response
Study: 3392892
Drug: Etomidate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 2.5 mg/h
Study: 3392892
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg/kg/h
Study: 25213687
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (routine medications replaced with study regimen to achieve blood pressure <140/90 mm Hg)
Study: 23462943
Drug: Dairy/Ca (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy/Ca (high dairy, ≈ 1400 mg/day Ca, ‐500 kcal/day)
Study: 23462943
Drug: Control (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (low dairy, ≈ 700 mg/day Ca, ‐500 kcal/day)
Study: 22263599
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g white sesame seeds daily
Study: 17288331
Drug: G‐Bond
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Bond
Study: 20225466
Drug: One-step adhesives
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step adhesives (Clearfil Tri‐S Bond and G‐Bond)
Study: 11479480
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) monotherapy, n = 16
Study: 11479480
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet drug (patient control), n = 16
Study: 11479480
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including ASA and TIC therapy)
Study: 7830324
Drug: Free therapy
Normalized name: Trolamine Salicylate 100 mg in 1 g TOPICAL CREAM [Equate Odor-Free Therapy Arthritis Analgesic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free therapy (by personal physicians without special intervention)
Study: 25617119
Drug: Aequasyal (oxygenated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aequasyal (oxygenated glycerol triester oral spray)
Study: 25617119
Drug: Biotene (moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotene (moisturizing spray)
Study: 21336679
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy-based weight management program (n=44)